Swiss stocks – Factors to watch on July 13

ZURICH, July 13 (BestGrowthStock) – Swiss stocks are seen opening a
bit firmer on Tuesday, in line with other markets across Europe
as confidence rises in the wake of forecast-beating figures from
U.S. group Alcoa (AA.N: ).

The Swiss blue-chip index SMI (.SSMI: ) was indicated to open
2 points higher at 6,231 points, premarket data provided by bank
Clariden Leu showed. (CLPRE: )

The following are some of the main factors expected to
affect Swiss stocks on Tuesday:

NESTLE (NESN.VX: )

Luxury cosmetics group L’Oreal, in which Nestle owns a 30
percent stake, posted higher revenue in the second quarter
helped by emerging markets and positive currency effects,
confirming a recovery in consumer spending that started earlier
this year.

For related news, click on [NESN.VX]

UBS (UBSN.VX: )

UBS, battling hard to keep its star U.S. brokers in place
after a tax evasion scandal, says it has turned the tide of
defections.

For related news, click on [UBSN.VX]

NOVARTIS (NOVN.VX: )

The American Society of Clinical Oncology issued new
guidelines on Monday for the use of hormone-based breast cancer
drugs called aromatase inhibitors.

Aromatase inhibitors include anastrozole, made by
AstraZeneca (AZN.L: ) under the brand name Arimidex, exemestane,
made by Pfizer Inc (PFE.N: ), under the brand name Aromasin and
Novartis’s Femara or letrozole.

For related news, click on [NOVN.VX]

ECONOMY [M-CH]

* Swiss producer and import price data are due at 0715
GMT.(ECONCH: )

COMPANY STATEMENTS [CNR-CH]

* Partners Group’s (PGHN.S: ) client demand results in inflows
of 3.0 billion Sfr (EUR 2.1 billion) during the first half of
2010.

Partners Group is increasing its guidance to EUR 4 billion
in assets raised for the full year 2010, which translates into
5.0-5.5 billion Sfr. [PGHN.S]

* Addex Pharmaceuticals Ltd. (ADXN.S: ) announced today that
its preclinical drug candidate ADX71943 was effective in a model
of osteoarthritis pain.[ADXN.S]

* Human Genome Sciences, Inc. and Lonza (LONN.VX: ) today
announced an agreement for the future commercial supply of
BENLYSTA, which is currently under regulatory review in the
United States and Europe as a potential new treatment for
systemic lupus erythematosus (SLE).

* Nobel Biocare (NOBN.VX: ) received notification that UBS had
a change to the composition of its group per 6 July 2010 and
held 4.11 percent of the registered share capital of Nobel
Biocare at that time.[NOBN.VX]

* Roche (ROG.VX: ) obtains co-exclusive license to develop PCR
assays detecting mutations in the PI3K oncogene. [ROG.VX]

* ALTIN (ALTN.S: ) announces portfolio holdings as at 1st July
2010. [ALTN.S]

EQUITY RESEARCH [CH-RCH]

* Citigroup lowers ABB (ABBN.VX: ) price target to 25 Sfr from
26.30 Sfr

* JP Morgan raises SGS (SGSN.VX: ) price target to 1,524 Sfr
from 1,507 Sfr

* BOFA Merrill raises SGS price target to 1,650 Sfr from
1,500 Sfr

* Goldman Sachs raises Nestle (NESN.VX: ) price target to
61.80 Sfr from 56.30 Sfr

* Goldman Sachs raises Aryzta (ARYN.S: ) price target to 38.90
Sfr from 37 Sfr

FOR COMPANIES TRADING EX-DIVIDEND, PLEASE CLICK ON:

(.EX.S: ) for all Swiss stocks

(.EXSMI.S: ) for blue chips

(.EXNSMI.S: ) for other stocks

Swiss stocks – Factors to watch on July 13